Literature DB >> 22776542

Successful use of canakinumab in a patient with resistant Behçet's disease.

L Cantarini, A Vitale, M Borri, M Galeazzi, R Franceschini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22776542

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  20 in total

1.  PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.

Authors:  Luca Cantarini; Antonio Vitale; Giulia Bersani; Laura Martin Nieves; Marco Cattalini; Giuseppe Lopalco; Francesco Caso; Luisa Costa; Florenzo Iannone; Giovanni Lapadula; Mauro Galeazzi; Angela Ceribelli; Enrico Brunetta; Carlo Selmi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2015-02-10       Impact factor: 2.980

2.  Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study.

Authors:  Giacomo Emmi; Rosaria Talarico; Giuseppe Lopalco; Rolando Cimaz; Fabrizio Cantini; Ombretta Viapiana; Ignazio Olivieri; Matteo Goldoni; Antonio Vitale; Elena Silvestri; Domenico Prisco; Giovanni Lapadula; Mauro Galeazzi; Florenzo Iannone; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2015-07-10       Impact factor: 2.980

3.  Development of de novo major involvement during follow-up in Behçet's syndrome.

Authors:  Rosaria Talarico; Luca Cantarini; Anna d'Ascanio; Michele Figus; Benedetta Favati; Chiara Baldini; Chiara Tani; R Neri; Stefano Bombardieri; Marta Mosca
Journal:  Clin Rheumatol       Date:  2015-03-08       Impact factor: 2.980

Review 4.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

5.  [Update: Behçet's disease].

Authors:  I Kötter
Journal:  Z Rheumatol       Date:  2012-11       Impact factor: 1.372

Review 6.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

7.  Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Authors:  Claudia Fabiani; Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Lorenzo Vannozzi; Silvana Guerriero; Stefano Gentileschi; Daniela Bacherini; Rossella Franceschini; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-12-16       Impact factor: 2.980

8.  Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.

Authors:  Luca Cantarini; Giuseppe Lopalco; Antonio Vitale; Laura Coladonato; Donato Rigante; Orso Maria Lucherini; Giovanni Lapadula; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2014-04-15       Impact factor: 2.980

Review 9.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690

Review 10.  Current and future treatments for Behçet's uveitis: road to remission.

Authors:  Marina Mesquida; Blanca Molins; Victor Llorenç; María Victoria Hernández; Gerard Espinosa; Andrew D Dick; Alfredo Adán
Journal:  Int Ophthalmol       Date:  2013-06-01       Impact factor: 2.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.